Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

MpowerTM may improve hair growth and satisfaction more than plain minoxidil, with mild side effects.

This study observed that 2% minoxidil solution stopped hair loss and promoted new hair growth in 85% of female pattern androgenetic alopecia patients, while 2% progesterone solution achieved similar results in 71% of patients.

This study developed and validated a reverse phase liquid chromatography method to accurately and reliably measure Minoxidil and Finasteride in bulk and marketed formulations.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

This study suggests that adding androgens to menopausal hormone therapy may reduce breast cancer risk by counteracting estrogen-driven proliferation in postmenopausal breast tissue.

This review discusses finasteride, developed by Merck, as a treatment for benign prostatic hyperplasia and notes its potential effectiveness for male androgenetic alopecia, but reports no new clinical results.

In this retrospective chart review, researchers observed that estrogen monotherapy effectively suppressed testosterone levels below 50ng/dL in all transfeminine patients studied, particularly those using injectable formulations, though the small sample size and ongoing data collection limit these findings.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

The study concluded that poly(propylene carbonate maleate) microspheres effectively encapsulated finasteride, achieving a biphasic release with prolonged drug release over 5-6 weeks in vitro.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

Dutasteride may become the top choice for treating hair loss.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This article describes the synthesis of novel polyamine-modified minoxidil analogs and conjugates to potentially enhance minoxidil's biological activity, selectivity, and water solubility, but reports no new biological results.